×

Sente, Inc. Appoints Randy W. Kriech as Chief Commercial Officer

company logo

SAN DIEGO, July 22, 2014 (GLOBE NEWSWIRE) -- Sente Inc., a privately held specialty aesthetics company pioneering the development of differentiated medical grade skincare products based on the science of glycoproteins, today announced the appointment of Randy W. Kriech as chief commercial officer. In his new role, Mr. Kriech will be responsible for leading global marketing, commercial operations and portfolio management. Mr. Kreich will report to Michael York, chief executive officer, and will be a key member of the Sente, Inc. executive management team.

"Randy is a respected commercial leader in the aesthetic space and we are thrilled to gain his insight and vision to help guide our company and management team," said Michael York, president and chief executive officer of Sente, Inc. "With his extensive commercial and leadership experience in the aesthetic skincare industry, Randy will be invaluable to Sente as we mature in size and complexity. His unique set of capabilities will enhance our commercial opportunities as we grow our science based skin care product portfolio based on our proprietary formulation of heparan sulfate on a global scale."

Mr. Kriech brings to Sente, Inc. nearly 20 years of management and commercial experience in the dermatology industry with more than 13 years focused on the development and marketing of aesthetic skincare products. Most recently, Mr. Kriech was Vice President of Sales and Marketing at PrecisionMD, the aesthetic division of Precision Dermatology, where he was responsible for leading worldwide commercialization of the PrecisionMD portfolio. Mr. Kriech has held management roles with a number of companies during their start-up phase within the dermatology marketplace, including SkinMedica and Celfix Cosmeceuticals, in which he was Co-Founder and Owner. Mr. Kriech holds a Bachelor of Arts degree in Communications from the University of Colorado, Boulder.

"Sente has established a strong foundation for commercial success," said Mr. Kriech, chief commercial officer of Sente, Inc. "I am looking forward to achieving our vision of becoming a recognized leader that brings differentiated new molecules, products and science to fulfill unmet needs in the skincare market."

Sente Dermal Repair Cream, is the first physician dispensed dermatological product from Sente, was launched in 2013 and helps the body replenish the essential skin building blocks that are lost with aging and UV exposure. It features a proprietary formulation of low molecular weight heparan sulfate, or HS, which is the most biologically active of the glycoproteins that reside in all layers of human skin. This biologically active low molecular weight HS analogue used in Senté Dermal Repair Cream has been shown to increase skin hydration, gradually brighten the appearance of pigmented lesions and soothe irritated skin.

About Sente, Inc.

Sente, Inc. is a privately held specialty aesthetics company leveraging its expertise and foundation in biotechnology to deliver novel, science-based skin care products. Senté is a recognized leader in the development of innovative and targeted medical skincare products based on glycoproteins. Sente recently launched its first physician dispensed dermatological product, Sente Dermal Repair Cream, which is currently the only aesthetic product utilizing low molecular weight heparan sulfate on the market today. HS is the most biologically active of the glycoproteins that reside naturally in human skin, and is responsible for regulating a wide variety of biological activities within the body. The biologically active glycoproteins used in Sente Dermal Repair Cream help increase skin hydration, gradually lighten the appearance of pigmented lesions and soothe irritated skin. Founded in 2007 and based in San Diego, California, further information may be found at http://sentelabs.com/. Sente products are available through our exclusive network of physicians, medically supervised spas and through Sentelabs.com.

CONTACT: Danielle Hale danielle@cmmpr.com

Source:Sente, Inc.